Late-breaking results show nipocalimab significantly improves Sjögren’s[...]
Genentech’s Phase III STARGLO Study Demonstrates Columvi Significantly[...]
03/22/2024 | Press release | Distributed by Public on 03/22/2024 07:15
Please select the service you want to use:
Smartlinks | Xalles Holdings Inc. | News | Health | Finance | Security Markets | Security Markets | Company News | Company Appointments | Corporate Officer Change | Securities Issuers | Blockchain and Cryptocurrency Companies | OTC Markets
Back
Copyright ©2006-2024 Public Technologies Inc. | Privacy Policy | Terms of Use | Contact